Hemcheck Sweden AB and Foundation for Innovative New Diagnostics (FIND) have signed an agreement regarding delivery of reader and one-time tests (v-Test). The order is a first evaluation order and is worth 9700 Euro.
–It’s very positive that we have received this order from FIND and that they want to evaluate the potential in using our products, since FIND is an attractive potential global partner. This is hopefully a first step in a broader and long-term collaboration with FIND, says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
FIND is a global non-profit organization driving innovation in the development and delivery of diagnostics to combat major diseases affecting mainly the world’s poorest populations. FIND has a strategic collaboration with WHO and partners with global actors such as Bill & Melinda Gates Foundation, EU and USAID.
Read more at https://www.finddx.org/
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on July 13, 2020 at 08.00